Lyell is an immuno-oncology company dedicated to reprogramming T cells to achieve curative therapies for solid tumors. The company takes a deliberate approach to solving what it believes to be the major barriers to successful adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is combining its proprietary ex vivo genetic and epigenetic reprogramming technologies that address these barriers with T cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptors (CARs). 

Therapeutics

Biotechnology

Lyell Immunopharma

Lynn Seely

Chris Michon

Manjit Dokal

Stasiu Nowak

Julie Urvater

Vonnie Vo

Erik Green

Eric Hoffmann

Karen Duffy-Simons

Julie Jeffery

Rick Watt

Danielle Kulman

Kimberly Henson

Wen Liu

Shipra G.

Joseph Maguire

Ellen Rose

Matthew Lang

Charles Newton

Tina Albertson

Gary Lee

Stephen Hill

The Scientific Research and Development team at Lyell Immunopharma is focused on advancing the company's mission to reprogram T cells for curative cancer therapies. Comprising experts in molecular biology, immunology, and computational biology, the team tackles challenges such as T cell exhaustion and loss of durable stemness. They employ cutting-edge genetic and epigenetic reprogramming technologies alongside TCRs, TILs, and CARs to develop innovative adoptive T cell therapies aimed at overcoming solid tumors.

Scientific Research and Development

Supply Chain and Manufacturing Team

Directorate Team

Scientific Research and Development

About

Team members

Other teams at Lyell Immunopharma

Supply Chain and Manufacturing Team

Directorate Team